



ANDA 211239

ANDA APPROVAL

Lupin Pharmaceuticals, Inc.
U.S. Agent for Lupin Limited
111 South Calvert Street
Harborplace Tower, 21st Floor
Baltimore, MD 21202
Attention: Debashis Mohanty
Associate Director - Regulatory Affairs

Dear Debashis Mohanty:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on October 25, 2017, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Bromfenac Ophthalmic Solution, 0.075%.

Your product is a combination product as defined by 21 CFR 3.2(e) and is comprised of drug and device constituent parts.

Reference is also made to the complete response letter issued by this office on June 2, 2023, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Bromfenac Ophthalmic Solution, 0.075% to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries Limited (Sun Pharmaceutical).

The RLD upon which you have based your ANDA, Sun Pharmaceutical's BromSite Ophthalmic Solution, 0.075%, is subject to a period of patent protection. The following patent and expiration date is currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,778,999 (the '999 patent)	August 7, 2029

Your ANDA contains a paragraph IV certification to the '999 patent, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Bromfenac Ophthalmic Solution, 0.075%, under this ANDA. You have notified the Agency that Lupin Limited (Lupin) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. Litigation was initiated within the statutory 45-day period against Lupin for infringement of the '999 patent in the United States District Court for the District of New Jersey [Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., v. Lupin Ltd. and Lupin Pharmaceuticals, Inc., Civil Action No. 18-02213]. You have also notified the Agency that this case was dismissed.

With respect to 180-day generic drug exclusivity, we note that Lupin was the first ANDA applicant for Bromfenac Ophthalmic Solution, 0.075%, to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Lupin may be eligible for 180 days of generic drug exclusivity for Bromfenac Ophthalmic Solution, 0.075%. The Agency notes that Lupin failed to obtain tentative approval of its ANDA within 30 months after the date on which the ANDA was filed. See section 505(j)(5)(D)(i)(IV) of the FD&C Act (forfeiture of exclusivity for failure to obtain tentative approval). The Agency is not, however, making a formal determination at this time of Lupin's eligibility for 180-day generic drug exclusivity. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



John
Ibrahim

Digitally signed by John Ibrahim

Date: 2/02/2024 02:48:51PM

GUID: 542af06d0124375c12e8c1d9fc86e87c